Here are the biggest fresh dividend hikes and special dividends, as first covered on InvestingPro+, including several predicted by data from Investing.com and StreetInsider last...
By Michael Erman (Reuters) – U.S. drugmaker Merck & Co hopes to patent a new formulation of its $20 billion cancer immunotherapy Keytruda that can be injected under the skin,...
Companies often establish a pattern of hiking dividends at the same time each year, giving investors a reliable cash influx and enticing them to stick around for the long term....
New collaboration builds on encouraging clinical data previously reported from INSIGHT-004 in multiple solid tumour indications from the combination of eftilagimod alpha (“efti”)...
Rising rates, accelerating inflation, and slowing economy hammered S&P 500 Energy and healthcare shares have been the market’s top gainers Investors should consider...
Drugmaker Merck's (NYSE:MRK) stock has outperformed its competitors year to date (ytd), rising 30.6%. Pfizer (NYSE:PFE), which I am bearish on, is down 16.9% so far this year. The...
Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. It serves drug wholesalers and retailers, hospitals, and government agencies; managed health care providers, such as health maintenance organizations, pharmacy benefit managers, and other institutions; and physicians and physician distributors, veterinarians, and animal producers. The company has collaborations with AstraZeneca PLC; Bayer AG; Eisai Co., Ltd.; Ridgeback Biotherapeutics; and Gilead Sciences, Inc. to jointly develop and commercialize long-acting treatments in HIV. Merck & Co., Inc. was founded in 1891 and is headquartered in Kenilworth, New Jersey.
| Average | 109.61 (-1.13% Downside) |
| High | 125.00 |
| Low | 97.00 |
| Price | 110.86 |
| No. of Analysts | 27 |
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Buy | Strong Buy | Strong Buy | Strong Buy | Strong Buy |
| Technical Indicators | Strong Buy | Strong Buy | Strong Buy | Strong Buy | Strong Buy |
| Summary | Strong Buy | Strong Buy | Strong Buy | Strong Buy | Strong Buy |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 12.60 | 12.60 | 12.60 | 0.00 | 0.00% | 0.00 | Toronto | |||
| 28.25 | 28.28 | 28.15 | +0.12 | +0.41% | 56.56K | Toronto | |||
| 4.05 | 4.21 | 3.97 | -0.1100 | -2.64% | 0.00 | Toronto | |||
| 0.07 | 0.07 | 0.05 | 0.00 | 0.00% | 0.00 | TSXV | |||
| 8.32 | 8.49 | 8.30 | -0.05 | -0.60% | 23.95K | Toronto | |||
| 0.05 | 0.06 | 0.05 | 0.00 | 0.00% | 0.00 | TSXV | |||
| 0.085 | 0.085 | 0.085 | 0.00 | 0.00% | 0.00 | CSE | |||
| 1.49 | 1.56 | 1.41 | +0.12 | +8.76% | 86.52K | Toronto | |||
| 3.78 | 3.78 | 3.78 | +0.02 | +0.53% | 258.00 | Toronto | |||
| 0.51 | 0.55 | 0.50 | 0.00 | 0.00% | 0.00 | TSXV | |||
| 61.20 | 61.20 | 61.20 | -0.07 | -0.11% | 200.00 | Toronto | |||
| 1.63 | 1.63 | 1.62 | +0.0200 | +1.24% | 32.56K | Toronto | |||
| 1.44 | 1.45 | 1.40 | 0.00 | 0.00% | 0.00 | Toronto | |||
| 9.72 | 9.74 | 9.61 | +0.070 | +0.73% | 16.18K | Toronto | |||
| 3.56 | 3.56 | 3.33 | +0.080 | +2.30% | 22.34K | Toronto |